Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size
Uncategorised

$100m-$499m

Thrive Earlier Detection identifies $110m series A
Thrive will commercialise a blood test for multiple early-stage cancers based on research at Johns Hopkins University, following a series A round backed by Blue Cross and Blue Shield Association.
AlloVir secures $120m funding allocation
The T-Cell therapy developer, based on research at Baylor College of Medicine, has received funding in a Gilead Sciences-backed series B round led by Fidelity Management and Research.
GetYourGuide goes to $484m series E
ETH Zurich spinout GetYourGuide secured $484m in a round led by SoftBank Vision Fund that took its total funding past $650m.
Zipline speeds up with $190m
Stanford-backed medical supplies delivery service Zipline has revealed two funding rounds totaling $190m, one of which is a $70m series C that included existing backer GV.
Byton moves closer to $500m series C
FAW Group will reportedly provide $100m for TUS Holdings-backed Byton for a $500m round likely to value the electric SUV developer at more than $2.5bn.
Coursera signs up for $103m series E module
Seek Group led a series E round that valued Coursera at more than $1bn, boosting the Stanford-founded online education provider’s total funding to more than $313m.
Talaris takes home $100m series A
Talaris, previously known as Regenerex and based on research at University of Louisville, will use the funding to advance its cell therapy into later-stage clinical development.
Sila Nano recharges with $170m
Battery materials developer Sila Nanotechnologies, co-founded by Georgia Tech professor Gleb Yushin, is preparing for commercialisation, after Daimler led a series E round.

Other News

AskBio pops $235m question
Asklepios BioPharmaceutical, based on work by UNC Chapel Hill professors Jude Samulski and Xiao Xiao, has secured $235m in funding co-led by TPG Capital and Vida Ventures.
Fusion gets reaction in $105m series B
Varian led a round for the targeted cancer drug developer that included existing investors such as Facit and Johnson & Johnson.
SambaNova snags $150m
Stanford-founded AI application platform developer SambaNova has raised $150m in a series B round led by Intel Capital that also featured existing investor GV.
Beam hits series B with $135m
GV participated as a new investor, as Harvard's genetic medicine developer Beam Therapeutics completed a round that followed $87m in series A funding last year.
Maze finds its way to $191m
GV and Alexandria have taken part in a $191m round to launch Maze Therapeutics with scientific co-founders from multiple universities such as Harvard and Stanford.
Passage Bio follows $116m series A trajectory
Passage Bio will develop therapies for diseases affecting the central nervous system based on research by James Wilson at Penn, after raising almost $116m in a series A round.

Editor's Picks

Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Immunocore smashes European biotech records
Immunotherapy firm Immunocore, which started life at Oxford University, raises the largest biotech round in European history.
test reg

Login